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http://www.ro-journal.com/content/7/1/222RESEARCH Open AccessHypofractionated radiotherapy for primary or
secondary oligometastatic lung cancer using
Tomotherapy
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Shang-Jyh Kao2 and Kwan-Hwa Chi1,3*Abstract
Background: To retrospectively review the outcome of patients with primary or secondary oligometastatic lung
cancer, treated with hypofractionated Tomotherapy.
Methods: Between April 2007 and June 2011, a total of 33 patients with oligometastatic intrapulmonary lesions
underwent hypofractionated radiotherapy by Tomotherapy along with appropriate systemic therapy. There were 24
primary, and 9 secondary lung cancer cases. The radiation doses ranged from 4.5 to 7.0 Gy per fraction, multiplied
by 8–16 fractions. The median dose per fraction was 4.5 Gy (range, 4.5-7.0 Gy), and the median total dose was
49.5 Gy (range, 45–72 Gy). The median estimated biological effective dose at 10 Gy (BED10) was 71.8 Gy (range,
65.3–119.0 Gy), and that at 3 Gy (BED3) was 123.8 Gy (range, 112.5–233.3 Gy). The mean lung dose (MLD) was
constrained mainly under 1200 cGy. The median gross tumor volume (GTV) was 27.9 cm3 (range: 2.5–178.1 cm3).
Results: The median follow-up period was 25.8 months (range, 3.0–60.7 months). The median overall survival (OS)
time was 32.1 months for the 24 primary lung cancer patients, and >40 months for the 9 metastatic lung patients.
The median survival time of the patients with extra-pulmonary disease (EPD) was 11.2 months versus >50 months
(not reached) in the patients without EPD (p < 0.001). Those patients with smaller GTV (≦27.9 cm3) had a better
survival than those with larger GTV (>27.9 cm3): >40 months versus 12.85 months (p = 0.047). The patients with ≦2
lesions had a median survival >40 months, whereas those with ≧3 lesions had 26 months (p = 0.065). The 2-year
local control (LC) rate was 94.7%. Only 2 patients (6.1%) developed ≧grade 3 radiation pneumonitis.
Conclusion: Using Tomotherapy in hypofractionation may be effective for selected primary or secondary lung
oligometastatic diseases, without causing significant toxicities. Pulmonary oligometastasis patients without EPD had
better survival outcomes than those with EPD. Moreover, GTV is more significant than lesion number in predicting
survival.
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Many cancer patients succumb to either primary or sec-
ondary lung cancer. Primary lung cancer is the leading
cause of cancer-related mortality all over the world. It
results in 20% of all cancer deaths in Taiwan, and ap-
proximately 25–30% in the United States [1]. Secondary* Correspondence: M006565@ms.skh.org.tw
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reproduction in any medium, provided the orlung cancer is observed in 30-60% of all cancer patients,
although prevalence varies on the basis of different pri-
mary cancer. Approximately 75–80% of primary lung
cancer patients have locally advanced stage III or IV dis-
ease at diagnosis, and late diagnosis has been an obstacle
to improving survival in the past several decades. How-
ever, primary lung cancer outcome has been greatly
improved in recent years owing to the introduction of
targeted and chemotherapy. Likewise, improved distant
control and overall survival of secondary lung cancer
has been perceived.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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for lung cancer treatment, the role of local therapy may
be more important because oligometastasis or oligore-
currence states are more frequent in the era of good but
not curative systemic therapy [2].
The paradigm of “oligometastasis” has long been
established in lung metastases from sarcoma and liver
metastases from colorectal cancer by Hellman and
Weichselbaum [3,4]. An intermediate state between
purely localized lesions and widespread systemic disease
does exist in many types of cancers. Before the cancer
cells acquire the ability to spread throughout the whole
body, local resection or ablative therapy with curative in-
tent may reduce the tumor burden and prolong the lives
of patients. By definition, the oligometastasis should be
confined to a small number of tumors in a limited num-
ber of organs. The detectable tumor sites should be
removed by surgery or radiation therapy.
Stereotactic radiation therapy (SRT) is an external
beam radiation procedure that has been widely used
since the 1990’s. It was initially used in small intracranial
or spinal tumors in a single fraction. Later, the technique
was applied to tumors outside the brain or spine, using a
stereotactic body frame, with 6–22 Gy/per fraction,
multiplied by 3–5 fractions [5]. This technique is called
stereotactic body radiation therapy (SBRT). Previous
studies evaluating SBRT for lung cancer mainly involved
T1–T2N0, medically inoperable patients with a 2-year
local control rate of approximately 90–95%, and varied
OS rate (3-years: 40–70%) [6-9]. Regarding oligometasta-
sis treated by SBRT, the weighted 2-year LC rate of:
77.9% (67–96%), and weighted 2-year OS rate of 53.7%
(33–89%) were presented in a systemic review [10].
The concept of SBRT has also been transformed into
hypofractionated radiotherapy (HRT) with a conven-
tional immobilization cast and a treatment course of
usually more than 8 fractions by the emergence of
image-guided techniques. The reliability of treating lung
tumors by HRT with a conventional immobilization cast
can be much improved by Tomotherapy. There are 2
advantages of Tomotherapy: (1) image-guided technique:
megavoltage computed tomography (MVCT) before
each treatment may be easily applied, and precise daily
tumor targeting may avoid the stringent hypofractio-
nated schedule; (2) MVCT is a slow CT scan that may
more accurately captured cephalad and caudal margins
during respiratory movement and is suitable for treat-
ment planning.
The efficacy and feasibility of HRT by Tomotherapy with
a conventional immobilization cast has not yet been widely
reported. In this study, we retrospectively reviewed our
experience of treating primary or secondary lung cancer
with Tomotherapy in hypofractionation. We assess the LC
rate, biological effective dose, overall survival and toxicities.Materials and methods
Patient characteristics
We retrospectively evaluated 33 patients who underwent
HRT with Tomotherapy (TomoTherapy Incorporated,
Madison, WI) for primary and secondary lung tumors
with curative intent at Shin Kong Hospital between
April 2007 and June 2011. Secondary lung cancer is can-
cer that originates in somewhere else in the body and
spreads to the lungs. Operability was discussed by a
multidisciplinary board before treatment. All patients
have signed the consent before the treatment. Bone
scans and FDG-PET scans were performed in selected
patients. Our department policies of using PET/CT as
complementary tool on primary or secondary lung can-
cer before radiotherapy are basically based on the fol-
lowing criteria: (1) to determine the resectability (2) to
determine the state of oligometastasis (3) to guide for
radiotherapy field. Fewer than 5 targets inside the tho-
racic region were required. The size of each primary
tumor was required to be <5 cm. Lung-to-lung metasta-
sis or mediastinal lymph node lesions were allowed, but
overall, there should be less than 5 individual gross
tumor volumes (GTVs).
MVCT simulation
All the patients were immobilized using conventional
thermoplastic frames with a diaphragm compressor to
control the amplitude of respiration to less than 15 mm,
which was investigated under fluoroscopy. MVCT was
performed for treatment planning in slices of 3-mm
thickness, and the images were then transferred to the
Tomotherapy planning station, HiArt version 4.04. All
MVCT scans were fused with conventional CT or PET/
CT scans for contouring.
Delineation of target volumes
The planning target volume (PTV) was 3 mm added to
the clinical target volume (CTV), which covered the
GTV plus an expansion of 5 mm from MVCT. The nor-
mal organs at risk (OAR) for potential radiation injury
must be contoured. For lung tumors, the OAR may in-
clude (1) the spinal cord, (2) esophagus, (3) heart, and
(4) lung. At least 93% of the prescription dose was
required to cover 99% of the PTV. The maximum dose
could not exceed 125% of the prescribed dose while ful-
filling dose constraints for the lung (each mean lung
dose [MLD] < 15 Gy, V5Gy < 42%), spinal cord (Dmax <
30 Gy), and heart (mean < 26 Gy). To calculate the
MLD, a contour comprising the volume of each lung
minus the GTV was constructed.
Dose-volume analysis of treatment plans
The prescribed doses for primary lung cancers were
between 450 and 500 cGy per fraction for 8–16 fractions




Age (years) Range 31-82
Median 68
Performance Status 0 20
1 10
2 3
Primary tumor site Lung 24
Mesothelioma 1






Primary lung cancer Stage IV 24
Extrapulmonary disease No 18
Yes 15





Concurrent systemic therapy No 10
Yes 23
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with 8–16 fractions for mediastinal lymph nodes. The
doses for metastatic lung cancers ranged from 450 to
700 cGy per fraction for 8–16 fractions. MLD was con-
trolled mainly under 1200 cGy according to the lung
cancer radiotherapy protocol in our department. The
Tomotherapy treatment plan was a pitch of 0.287, a
width jaw setting of 2.5 cm, and a modulation factor of
3.0. All the plans were assessed and doubly checked by 2
individual medical physicists. Once the optimization was
completed, the radiation oncologist reviewed the isodose
distributions for final approval of the treatment plans.
According to general recommendations, the biological
effective dose (BED) calculations are at 3 Gy (BED3) for
late-responding tissue and radiation pneumonitis (RP),
and at 10 Gy (BED10) for lung tumors. We used the for-
mula from Dale et al. [11], in which the adopted K value
of 0.9 Gy day−1 represents the BED required each day
(after Tdelay has been passed) to offset repopulation, and
Tdelay has a working value of 28 days.
Systemic therapy
Most patients underwent systemic therapy including
chemotherapy/tyrosine kinase inhibitor (TKI) before and
after radiotherapy. The thoracic irradiation of the
patients who developed extrapulmonary disease (EPD)
within 3 months after the treatment was considered as
ineffective systemic therapy, and the treatment results
were analyzed as EPD-positive.
Toxicity and tumor control
All the patients were evaluated at least once a week du-
ring the radiotherapy (RT) period for acute toxicity.
Follow-up lung CT scans were carried out at least
1.5 months after the completion of radiotherapy and at
3-month intervals thereafter. The RP grade was evalu-
ated according to the Acute Radiation Morbidity Scoring
Criteria and The Radiation Therapy Oncology Group
(RTOG)/European Organisation for Research and Treat-
ment of Cancer (EORTC) Late Radiation Morbidity
Scoring Schema. The tumor response was assessed
according to the Response Evaluation Criteria In Solid
Tumors (RECIST) criteria. The recurrence patterns were
classified as “in-field” if >95% of the volume was within
the 95% isodose, “marginal” if 20–95% of the volume
was within the 95% isodose, or “outside” if <20% of the
volume was inside the 95% isodose [12].
Statistical methods
Kaplan-Meier estimates of survival curves were com-
puted for median OS. Comparisons of median OS rates
were performed using the log-rank test. The Pearson
correlation was also calculated to reflect the degree of
the linear relationship between 2 different variables.Owing to the small number of subjects, a multivariable
analysis was not conducted. The SPSS (version 13) soft-
ware was used for all the data analyses.
Results
Patient characteristics
As shown in Table 1, 24 male and 9 female patients,
with a median age of 68 years (range: 31–82 years), were
evaluated. The median follow-up period was 25.8 months
(range, 3.0–60.7 months). Twenty-four patients had
primary lung cancer (72.7%), and 1 patient had recurrent
mesothelioma; 8 secondary lung cancer cases included 3
from the colorectum, 1 from the esophagus, 1 from the
stomach, 1 from the liver, 1 from the head and neck,
and 1 from sarcoma. The 24 primary lung cancer patients
were all stage IV cancer. Eighteen cases (75.0%) were
adenocarcinoma; 3 (12.5%), squamous cell carcinoma; and
3 (12.5%), unspecified non-small cell lung cancer
(NSCLC). The data of tumor volume, healthy lung vol-
ume, and max spinal cord dose were illustrated in Table 2.
The median GTV was 27.9 cm3 (range: 2.5–178.1 cm3).
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1235.5–4221.3 cm3). The median max spinal cord dose
was 14.1 Gy (range: 2.0-37.4 Gy), and only 2 patients
exceeded 30 Gy.
Chemotherapy/target therapy
Among the 24 lung cancer patients, all underwent sys-
temic treatment before and after radiotherapy.
Eighteen patients (75%) underwent concurrent sys-
temic therapy during radiotherapy. The mainstay regi-
men of all 24 patients included: TKI (either Iressa orTable 2 Data of tumor volume, healthy lung volume, and Dm
Case GTV (cm3) R’t lung-GTV (cm3) L’t lung-GTV (c
1 146.9 1227.1 771.7
2 11.3 1638.8 1640.0
3 50.7 1308.0 1111.1
4 52.0 2183.1 2038.2
5 65.5 682.9 632.1
6 12.8 1323.6 985.4
7 4.1 776.9 458.6
8 19.8 936.2 892.9
9 28.9 1577.6 1164.8
10 70.6 2187.3 1990.3
11 45.4 1720.7 1591.6
12 69.2 2163.3 1407.4
13 6.8 1012.7 536.7
14 27.9 955.1 955.2
15 18.9 1155.7 1443.7
16 20.6 1042.4 1180.7
17 35.1 1333.5 1102.1
18 36.9 1213.7 938.0
19 39.2 1742.5 1861.8
20 12.5 1346.6 1231.2
21 13.2 1725.0 1245.3
22 178.1 2022.6 987.2
23 27.9 1408.5 853.5
24 3.9 1057.3 605.3
25 6.4 681.7 657.6
26 47.9 1266.1 774.7
27 47.7 1741.8 1341.4
28 2.5 833.9 1102.0
29 30.0 1267.3 816.9
30 13.2 1052.1 617.5
31 44.4 2250.2 1849.8
32 27.0 1978.7 1582.0
33 20.7 1153.0 980.5Tarceva) in 13 patients, Navelbine in 7 patients, Alimta
in 2 patients, and Cyclophosphamide (Endoxan) +
Uracil-Tegafur (UFUR) in 2 patients. No patients
received gemcitabine (Gemzar) based regimen during
radiotherapy course. All the adenocarcinoma patients
received TKI in the course of their long-term treatment,
which might be concurrently with, before, or after radio-
therapy. The 9 other patients had secondary lung can-
cers, of whom 3 underwent RT alone (33.3%), 2 received
thalidomide, 3 received capecitabine (Xeloda) based regi-
men, and 1 received Uracil-Tegafur (UFUR) alone. Allax of spinal cord
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with metastatic colorectal cancer continued their sys-
temic therapy programs.
Total radiation doses and treatment duration
The median fraction size was 4.5 Gy (range, 4.5–7.0 Gy/
fx), and the median total dose for lung oligometastasis
was 49.5 Gy (range, 45–72 Gy). The median overall
treatment time (T) was 14.5 days (range, 10–27 days).
The median estimated BED10 was 71.8 Gy (range, 65.3–
119.0 Gy), and median estimated BED3 was 123.8 Gy
(range, 112.5–233.3 Gy).
Treatment outcome
As illustrated in Figure 1A and Table 3, the median sur-
vival of the patients with primary lung cancers (n = 24)
was 32.1 months. The overall survival rates at 1, 2, 3,
and 4 years were 65.2%, 55.9%, 39.9%, and 39.9%, re-
spectively. As shown in Figure 1B and Table 4, the sec-
ondary lung cancer patients (n = 9) had a median
survival > 40 months (not reached), and the overall sur-





































Figure 1 (A) Overall survival in oligometastatic primary lung
cancer patients (n = 24). The median survival was 32.1 months. (B)
Overall survival in secondary lung cancer patients (n = 9). Median
survival was not reached.66.7%, and 66.7%, respectively. As shown in Figure 2,
the patients with EPD (n = 15) had a median survival of
11.2 months, whereas those without EPD (n = 18) had a
longer median survival (>50 months, not reached; p <
0.001). We also analyzed the relationship between the
numbers of intrathoracic metastatic lesions of ≤2 and ≥3
in Figure 3. There was no significant difference in sur-
vival between the 2 groups: >40 months (not reached)
versus 26 months (p = 0.065). As shown in Figure 4A
and B, the influence of EPD status on overall survival
was significant in the primary lung cancer cases but not
in the secondary lung cases. In the primary lung cancer
group, the survival of the EPD-negative group versus the
EPD-positive group was >50 months (not reached) ver-
sus 9.7 months, respectively (p = 0.011). At the end point
of the follow-up period, 33 patients with 65 intrapul-
monary lesions were investigated, and only 1 lesion had
in-field local recurrence. The 2-year LC rate was 94.7%.
Tomotherapy without systemic treatment may be cura-
tive for secondary lung metastatic lesions without EPD.
One sarcoma patient was still alive 60.5 months after
RT, 1 rectal cancer patient was still alive 53.7 months
after RT, and 1 colon cancer patient was still alive
43.7 months after RT.
Dosimetric analysis
The median GTV was 27.89 cm3 (range: 2.54–178.08 cm3).
There was a weak positive linear correlation between
MLDs and GTVs, with a Pearson correlation of 0.682. This
correlation is illustrated in Figure 5. Patients with a smaller
sum of intrapulmonary GTVs seemed to have better OS,
as shown in Figure 6. Those whose GTVs were smaller
than the median value of 27.89 cm3 had a median survival
> 40 months (not reached), whereas the patients with a
GTV larger than 27.89 cm3 had a median survival of only
12.85 months (p = 0.047).
Acute and late toxicity
During the follow-up examination, we found that 13
patients (39.4%) had grade 0 RP, 14 (42.4%) had grade 1
RP, and 4 (12.1%) had grade 2 RP. There were 2 patients
(6.1%) who developed ≥ grade 3 RP. The median value of
MLD in the grade 0 RP group was 415.0 cGy; in the
grade 1 RP group, 831.5 cGy; in the grade 2 RP group,
1011.5 cGy; and in the grade 3 RP group, 1118.5 cGy.
The RP grade increased from grade 0 to 3 with a corre-
sponding increase in the median value of MLD. These
data are illustrated in Figure 7.
Discussion
This study reports our experience of hypofractionated
Tomotherapy for the treatment of oligometastatic pri-
mary or secondary lung cancer. We found that HRT in
combination with systemic treatment may be effective
Table 3 Characteristics of oligometastatic primary lung cancer (n = 24) receiving Tomotherapy










1 F 53 T4N2M1,IV NSCLC 450 × 10 5 TKI D 51.2
2 M 58 M1, IV AD 450 × 10 2 TKI D 40.6
3 M 31 M1, IV AD 450 × 10 3 CT (Alimta) A 39.0
4 M 59 M1, IV AD 450 × 11 3 CT (Navelbine) D 6.0
5 M 43 M1, IV AD 450 × 10 1 TKI D 13.4
6 M 79 T1NxM1,
IV
AD 500 × 9 2 CT(Endoxan + UFUR) D 8.2
7 F 49 T1N0M1,
IV
AD 500 × 9 1 CT (Alimta) A 29.7
8 F 80 M1, IV AD 450 × 10 1 TKI D 4.6
9 M 69 M1, IV AD 450 × 12 5 CT (Navelbine) D 5.1
10 M 79 T2N0M1,IV NSCLC 450 × 16 1 CT (Navelbine) D 6.7
11 M 64 T2N0M1,
IV
AD 550 × 10 1 TKI D 11.2
12 M 71 rT4, IV SqCC 500 × 12 1 CT (Navelbine) D 12.3
13 F 74 T4N2M1,IV AD 450 × 10 1 TKI A 26.2
14 M 73 rT1a,IV AD 450 × 10 1 TKI A 24.3
15 M 67 rT3,IV NSCLC 500 × 10 1 CT(Endoxan + UFUR) A 14.8
16 F 70 M1,IV AD 500 × 9 2 TKI A 20.0
17 F 45 M1,IV AD 550 × 10 1 TKI D 34.7
18 M 50 T2aN0M1,
IV
AD 500 × 10 1 TKI A 25.8
19 M 78 M1,IV SqCC 450 × 10 1 CT (Navelbine) D 4.2
20 M 47 rN1,IV AD 450 × 10 1 TKI A 41.6
21 M 68 T1N2M1,IV AD 450 × 10 5 TKI D 32.1
22 M 79 M1,IV AD 450 × 10 3 CT (Navelbine) D 3.0
23 F 79 rT3, IV SqCC 450 × 12 2 CT (Navelbine) A 60.7
24 F 58 M1b,IV AD 450 × 10 1 TKI A 10.1
M = male; F = female; AD = adenocarcinoma; SqCC = squamous cell carcinoma; NSCLC = non-small cell lung cancer; fx = fractions; A = alive; D = dead; TKI =
tyrosine kinase inhibitor (Erlotinib or Gefitinib); CT = chemotherapy.
Table 4 Characteristics of oligometastatic secondary cancer (n = 9) receiving Tomotherapy
Case Sex Age Stage Pathological
diagnosis






1 M 68 IVB HCC 500 × 8 + 450 ×
3
1 Thalidomide A 26.9
2 M 51 IV Sarcoma 700 × 10 1 Thalidomide A 60.5
3 M 71 IVC H&N SqCC 500 × 10 1 - D 6.3
4 M 61 IV Esophagus SqCC 600 × 8 1 - D 14.7
5 M 70 - Mesothelioma 500 × 10 1 - A 27.3
6 M 77 IV Colon AD 550 × 10 2 Xeloda A 43.7
7 M 82 IV Rectum AD 450 × 13 1 Xeloda A 53.7
8 M 63 IV Stomach AD 450 × 12 2 Xeloda A 37.2
9 F 77 IV Rectum AD 450 × 9 4 UFUR D 26.0
M = male; F = female; AD = adenocarcinoma; SqCC = squamous cell carcinoma; H&N = head and neck; fx = fractions; A = alive; D = dead.
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Figure 2 Relationship between EPD status and overall survival
rate. The EPD (−) group did not achieve median overall survival,
while the overall survival in the EPD (+) group was only 11.2 months
(p < 0.001).












































Figure 4 (A) EPD status in primary lung cancer also leads
survival difference. EPD(+) vs EPD(−): 9.7 months vs not reached
(p = 0.011). (B) EPD status in secondary lung cancer. EPD(+) vs EPD
(−): 26 months vs not reached (p = 0.150).
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predicted survival. To date, few studies have investigated
the use of hypofractionated Tomotherapy for advanced-
stage primary lung cancer. Adkison et al. [13] reported
the effectiveness of hypofractionated Tomotherapy for
inoperable NSCLC with 2.28–3.22 Gy per fraction, for a
total of 25 fractions in 46 patients. The median survival
time was 18 months, with an actuarial 2-year survival of
46.8% and a 6.5% in-field progression rate. However,
80% of their patient population had stage III cancers.
Song et al. [14] reported a 2-year survival rate of 56%
and a 2-year LC rate of 63% in 37 NSCLC patients after
hypofractionated Tomotherapy with 2.0–2.4 Gy per frac-
tion, at a total dose of 60–70.4 Gy. Again, 75.7% of their
patients had stage III cancer, 13.5% had stage I and II
cancers, and 10.8% had recurrent disease. However, all
of the patients in our study population had stage IV can-
cer and achieved a 2-year survival rate of 55.9% and a
median survival of 32.1 months. We believe that one of
the reasons for our results is that most of our lung can-
cer patients responded to the systemic targeted therapy.
Patients with oligometastatic lung tumors without





















Figure 3 Overall survival difference of 2 and 3 total
oligometastatic lesions in all 33 patients. Median survival were
undefined and 26 months separately (p = 0.065).those with EPD, regardless of treatment modality. Zhang
Ye et al. [15] reported that in patients with secondary
lung cancers who underwent SBRT, the 5-year survival
rate (33.2% vs 12.5%), median survival time (37.3 months
vs 18.2 months, p = 0.012), and hazard ratio (HR, 1.894;
p = 0.024) all favored negative EPD. Yamakado et al. [16]
presented a study of colon cancer with lung metastasis
treated with radio frequency ablation (RFA). They found
that the 5-year survival rate for the patients without
EPD was 57%, whereas that for the patients with EPD
was 0% (p < 0.0001). Surgical management of oligome-


















Figure 5 MLD vs GTV.





















Figure 6 Use GTV volume to predict survival.
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prognostic factor. The 3-year survival rates were 54.7%
for EPD-negative patients and 0% for EPD-positive
patients (p = 0.0411). A large series of pulmonary metas-
tasectomy for CRC conducted by Kanemitsu et al. [18]
also demonstrated that EPD was a poor prognostic
factor, with HRs of 1.73 (univariate, p = 0.001) and
1.55 (multivariate, p = 0.021). The study conducted by
Schuhan et al. [19], which evaluated survival after pul-
monary metastasectomy in malignant melanoma, dis-
closed that before surgery, EPD-negative patients had a
median survival time of 39.8 months, compared with the
15.7 months (p = 0.23) in those with EPD. All of these
studies generated the same conclusion as ours: that the
median survival time of patients with EPD was
11.2 months, as compared with the >50 months (not
reached) in patients without EPD (p < 0.001).
The importance of the involved numbers of organs or
lesions in survival outcome was reported in 2 studies
[20,21]. On the contrary, a pilot study for SBRT con-
ducted by Milano et al. [21] disclosed that neither the
numbers of organs nor lesions involved could predict
survival (univariate, p = 0.43; multivariate, p = 0.50). Kim
et al. [20] reported that treatment of oligometastatic












Figure 7 MLD vs RP.survival in patients with ≤5 intrapulmonary lesions than
those with >5 lesions, but the difference was not statisti-
cally significant (17 months vs 10 months, p = 0.2323).
We observed a median OS time > 40 months versus
26 months in those with ≤2 versus those with ≥3 intra-
pulmonary lesions, respectively (p = 0.065).
Milano’s [21] prospective study also concluded that
smaller GTVs were significant for LC, distant control,
and survival benefit. Another long-term follow-up study
by Milano [22] also showed that greater SBRT target
volume in non-breast cancer was a poor prognostic fac-
tor for OS (p = 0.012). Our study also revealed that a
small intrapulmonary GTV (≤27.89 cm3) correlated with
better survival than a large GTV (≥27.89 cm3):
>40 months versus 12.85 months (p = 0.047). These
results are in accordance with the rationale of oligome-
tastasis that higher tumor burden beyond the threshold
size leads to an exponential rise in cell proliferation and
the risk of distant metastasis. GTV has proved to be
more significant than the number of metastatic lesions
or organs for predicting survival.
Stage IV lung cancer is a systemic disease. The sur-
vival benefit from good LC should be based on good sys-
temic control, and high LC rate alone would be
meaningless in systemic disease. We have previously
reported [23] that patients with mainly stage IV lung
adenocarcinoma may gain longer survival by taking
concurrent TKI plus multi-target Tomotherapy with a
smaller fraction size, that is, 250 cGy/fx, for a total of
20–25 fractions. The 3-year overall survival rate reached
62.5%, and the progression-free survival (PFS) time was
16 months. The results of this study implied that
early intervention of oligometastasis by radiotherapy in
patients with fair systemic control may prolong
progression-free survival and probably offer a greater
survival benefit than systemic therapy alone. In the
present study, we reviewed patients treated with
Tomotherapy with a higher fraction size (450–700 cGy
per fraction) and found a similar long survival rate but a
more impressive LC rate.
The outcome of oligometastatic primary or secondary
lung cancer treatment depends mainly on the nature of
the tumor and the response to systemic treatment.
Ideally, the oligometastatic state should be more indo-
lent in nature. Metastases that are limited in number
and location may be due to the fact that the metastatic
machinery has not matured at that time. Disease pro-
gression is just a matter of time, and tumors detected in
the oligometastatic state may be more vulnerable to
therapy. An aggressive approach such as early interven-
tion by local or multi-target radiotherapy in addition to
mainstream systemic therapy is important to avoid
malignant progression and drug resistance in response
to systemic therapy alone.
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http://www.ro-journal.com/content/7/1/222In our study, the RP grade was quite low, with only 2
patients (6.1%) having ≥3 RP and most patients having
grade 0 or 1 RP (81.8%), which is comparable with other
studies. Park et al. [24] evaluated the early CT findings
in 25 patients with pulmonary malignancies treated by
Tomotherapy. The median total dose was 50 ± 4.99 Gy
in 3–20 fractions. They reported that none of the
patients developed ≥ grade 3 RP. Adkison et al. [13] trea-
ted 46 lung cancer patients with hypofractionated
Tomotherapy with 2.28–3.22 Gy per fraction, for a total
of 25 fractions. They also reported a ≥ grade 3 RP rate of
0%. Song et al. [14] described a trial in which 37 NSCLC
patients treated with Tomotherapy with 2.0-2.4 Gy per
fraction, up to total 60–70.4 Gy, exhibited a higher ≥
grade 3 RP rate (19%). Generally, SBRT of smaller GTV
yields a lower ≥ grade 3 RP rate of 1.2–4% [25,26]. Refer-
ring to the report from Vofelius et al., Tomotherapy is
particularly safe in the range of 7 to 20 fractionation
schedule (RP risk ≦8%), while RP rate by 3D-CRT tech-
nique would be 10-12% in 7 to 20 fractions and even up
to 13-16% in ≦5 fractions [27].
The median fraction size of 4.5–6 Gy/fx to a median
total dose of 49.5 Gy was performed in our study. We
had a lower BED (median estimated BED10 was
71.78 Gy) than that provided by the widely used high-
fraction size SBRT technique (median BED10 ≥ 100 Gy in
most studies). Nonetheless, a 94.7% 2-year LC rate and a
6.1% severe RP rate make our protocol quite attractive.
Tomotherapy with conventional immobilization casts is
much more convenient than SBRT with a stereotactic
body frame. Furthermore, hypofractionated Tomother-
apy can treat a larger tumor size. It can also treat multi-
targets in the thorax and extrapulmonary regions at the
same time.Conclusion
The heterogeneity of tumor, small number of patients
and retrospective data collection are the 3 important
limitations of this study. Nevertheless, we can conclude
a few important observations. Firstly, hypofractionated
Tomotherapy with conventional immobilization cast
may be as good as SBRT with extreme hypofractiona-
tion. Secondly, oligometastasis confined in lung organ
only has better result than more than 2 organs involve-
ment. GTV volume is more significant than number of
metastatic lesions or organs involvement in predicting
survival. Thirdly, oligometastatic state created from era
of successful systemic treatment may highlight the im-
portance of early integrating HRT with systemic treat-
ment in primary and secondary lung cancer patients.
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